A new prescription drug aimed at extending the lifespan of dogs is moving closer to FDA approval. LOY-002, developed by the San Francisco biotech company Loyal, is a once-daily tablet designed for dogs aged 10 or older that weigh at least 14 pounds. It has already passed two of the three major technical requirements needed for conditional FDA approval, with the drug potentially becoming available as early as late 2026 or 2027.
Read More
This development is significant for an estimated 44 percent of pets classified as seniors by the American Animal Hospital Association. To clarify the implications of this drug, Dr. Rebecca Greenstein, a veterinarian and Chief Veterinarian at Kleinburg Veterinary Hospital in Ontario, explained that LOY-002 targets age-related metabolic changes rather than any specific disease. Dr. Greenstein emphasized that the term "anti-aging pill" could be misleading. She noted that the aim of LOY-002 is to improve insulin sensitivity and lower insulin blood levels, which might help extend a dog’s healthspan—the period spent in good health—rather than simply adding years to its life.
The concept behind LOY-002 is supported by a 14-year Purina study published in 2002, which demonstrated that Labrador retrievers fed a 25 percent reduced calorie diet lived nearly two years longer than their counterparts.
Loyal is also working on other drugs, LOY-001 and LOY-003, specifically targeting the unique aging processes in larger dog breeds. Research indicates that large dogs, such as Great Danes, tend to age and die faster compared to smaller breeds like Chihuahuas. Dr. Greenstein explained that multiple factors, including genetic variations and metabolic growth rates, influence these differences in lifespan.
As for the FDA's conditional approval process, Dr. Greenstein reiterated that this does not guarantee LOY-002 will make every dog live longer. Instead, it suggests that there is a reasonable expectation of its effectiveness, and further data must be gathered over the next several years. The initial conditional approval could last for one year and be renewable for up to five years while Loyal demonstrates more evidence of the drug's efficacy.
Veterinarians anticipate inquiries about the longevity pill once it becomes available. Dr. Greenstein cautioned that the drug may not be suitable for all senior dogs. Frail dogs or those with multiple health issues may not benefit as significantly as those in overall better health. She also noted that no medication can replace the value of a healthy lifestyle.
Dr. Greenstein would consider using LOY-002 for her own dog, but only after sufficient safety data is collected. She stressed that extending lifespan should not come at the cost of a dog's quality of life.
Loyal hopes that LOY-002 could provide at least an additional year of life for senior dogs, but Dr. Greenstein raised concerns about what that year would look like. The ongoing STAY study, a substantial trial across 70 veterinary clinics, is investigating not just the longevity benefits of LOY-002, but also its impact on the quality of life for dogs.
While awaiting the release of LOY-002, Dr. Greenstein recommends maintaining a healthy lifestyle for dogs through weight management, exercise, routine veterinary care, and early disease detection. These practices are considered fundamental for enhancing the healthspan of dogs.